Workpackage 5

Biological markers to predict the response of head and neck tumours to Cetuximab or cisplatin + RT

At the partner Institut Gustave Roussy in Villejuif, France, specific biological markers which have shown to have predictive or prognostic potential in head and neck as well as lung cancer will be evaluated in relation to the treatment outcome.  These biomarkers will aid the selection of patients who will benefit from either the combined treatment with RT and Cetuximab or with RT and cisplatin so that further individualisation of these treatments can be validated.

Clinical trials in lung and head and neck cancer will be carried out among the partners NKI (Amsterdam), Karolinska Institutet (Stockholm), the Institute Gustave Roussy (Villejuif) , Vall d’Hebron (Barcelona), The Christie (Manchester),UMCU (Utrecht) and Erasmus MC (Rotterdam) while the laboratory research will be carried out at INSERM (Paris).